PDX models are considered the gold standard in oncology drug development, as they maintain the original tumor architecture, ensuring that their histology and heterogeneity closely resemble the donor patient tissue. These models have not touched plastic and have not undergone monoclonal selection, making them fully established preclinical models with long-term availability.
Our team of scientists, armed with PDX expertise, guarantees quality and client success. We are continuously developing various methods to utilize PDX tissue, including both in vitro and ex vivo 3D assays.
PDX models are extensively utilized in preclinical trials for novel drugs, validating innovative drug combinations, chemotherapy, targeted therapy, immunotherapy, screening for drug-sensitive patients, and investigating mechanisms of drug resistance. The primary challenge lies in the scarcity of research tools that accurately reflect the true status of cancer in real-world patients.
This white paper describes that by harnessing PDX advantages with next-generation tools such as 3D technology and machine learning live cell imaging we can pave the way for a quicker path to clinical application.
Download the white paper to:
- Understand the benefits of PDX models.
- Learn how these new generation tools can quickly accelerate the efficacy study of your oncology drug development.
- Explore how to use PDX in vivo, in vitro/ex vivo, and in silico to speed up your development of different modalities, including cell therapy.
Offered Free by: CG Life
See All Resources from: CG Life
